Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 118

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

Zandi, Roza, Selivanova, Galina, Christensen, Camilla Laulund, Gerds, Thomas Alexander, Willumsen, Berthe Marie, Poulsen, Hans Skovgaard·2011·Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1Met (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Since p53 is mutated in more than 90% of SCLC, we investigated the ability of PRIMA-1Met to induce apoptosis and inhibit tumor growth in SCLC with different p53 mutations. Experimental Design: The therapeutic effect of PRIMA-1Met/APR-246 was studied in SCLC cells in vitro using cell viability assay, fluorescence-activated cell-sorting analysis, p53 knockdown studies, and Western blot analyses. The antitumor potential of PRIMA-1Met/APR-246 was further evaluated in two different SCLC xenograft models. Results: PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells. The growth suppressive effect of PRIMA-1Met/APR-246 was markedly reduced in SCLC cell lines transfected with p53 siRNA, supporting the role of mutant p53 in PRIMA-1Met/APR-246-induced cell death. Moreover, in vivo studies showed significant antitumor effects of PRIMA-1Met after i.v. injection in SCLC mouse models with no apparent toxicity. Conclusion: This study is the first to show the potential use of p53-reactivating molecules such as PRIMA-1Met/APR-246 for the treatment of SCLC. Clin Cancer Res; 17(9); 2830–41. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-3168

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 38

  1. Christensen, 2009, Specifically targeted gene therapy for small-cell lung cancer, Expert Rev Anticancer Ther, 9, 437, 10.1586/era.09.10 · DOI
  2. Cooper, 2006, Small cell lung cancer: treatment review, Respirology, 11, 241, 10.1111/j.1440-1843.2006.00850.x · DOI
  3. Lally, 2007, Small cell lung cancer: have we made any progress over the last 25 years?, Oncologist, 12, 1096, 10.1634/theoncologist.12-9-1096 · DOI · Paper page
  4. Viktorsson, 2005, The role of p53 in treatment responses of lung cancer, Biochem Biophys Res Commun, 331, 868, 10.1016/j.bbrc.2005.03.192 · DOI · Paper page
  5. Fuster, 2007, Classic and novel roles of p53: prospects for anticancer therapy, Trends Mol Med, 13, 192, 10.1016/j.molmed.2007.03.002 · DOI
  6. Chipuk, 2003, Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
  7. Rodriguez-Salas, 2001, Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas, Lung Cancer, 34, 67, 10.1016/S0169-5002(01)00230-6 · doi:10.1016/s0169-5002(01)00230-6
  8. Fujiwara, 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res, 54, 2287
  9. Rusch, 1995, Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer, Cancer Res, 55, 5038
  10. Adachi, 1996, Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma, Cell Growth Differ, 7, 879
  11. Nemunaitis, 2009, Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 · DOI
  12. Bykov, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
  13. Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411
  14. Bykov, 2003, Small molecules that reactivate mutant p53, Eur J Cancer, 39, 1828, 10.1016/S0959-8049(03)00454-4 · DOI
  15. Pedersen, 2003, Transcriptional gene expression profiling of small cell lung cancer cells, Cancer Res, 63, 1943
  16. Poulsen, 2008, A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells, Cancer Gene Ther, 15, 563, 10.1038/cgt.2008.24 · DOI
  17. Rehman, 2005, Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells, Breast Cancer Res, 7, R765, 10.1186/bcr1290 · DOI
  18. de Leij, 1985, Characterization of three new variant type cell lines derived from small cell carcinoma of the lung, Cancer Res, 45, 6024
  19. Bulte, 1993, Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes, J Neurooncol, 16, 11, 10.1007/BF01324829 · doi:10.1007/bf01324829
  20. Pettengill, 1980, Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung, Cancer, 45, 906, 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H · doi:10.1002/1097-0142(19800301)45:5<906::aid-cncr2820450513>3.0.co;2-h
  21. Carney, 1985, Establishment and identification of small cell lung cancer cell lines having classic and variant features, Cancer Res, 45, 2913
  22. Bepler, 1987, Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines, J Cancer Res Clin Oncol, 113, 31, 10.1007/BF00389964 · doi:10.1007/bf00389964
  23. Berendsen, 1988, Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up, Cancer Res, 48, 6891
  24. Wurtzen, 2001, Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line, Int J Cancer, 93, 855, 10.1002/ijc.1417 · DOI
  25. Forbes, 2006, COSMIC 2005, Br J Cancer, 94, 318, 10.1038/sj.bjc.6602928 · DOI · Paper page
  26. Hayes, 1999, Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue, Diagn Mol Pathol, 8, 2, 10.1097/00019606-199903000-00002 · DOI
  27. Hensel, 1991, Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer, Oncogene, 6, 1067
  28. Berglind, 2008, Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination, Cancer Biol Ther, 7, 699, 10.4161/cbt.7.5.5712 · DOI
  29. Nakamizo, 2008, Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis, Neuro Oncol, 10, 275, 10.1215/15228517-2008-015 · DOI
  30. Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI
  31. Shmueli, 2004, Regulation of p53 by Mdm2: fate is in the numbers, Mol Cell, 13, 4, 10.1016/S1097-2765(03)00529-X · DOI
  32. Muller, 2004, Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures, J Biol Chem, 279, 48846, 10.1074/jbc.M407687200 · DOI
  33. King, 2001, Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53, EMBO J, 20, 6297, 10.1093/emboj/20.22.6297 · DOI · Paper page
  34. Haupt, 1995, Induction of apoptosis in HeLa cells by trans-activation-deficient p53, Genes Dev, 9, 2170, 10.1101/gad.9.17.2170 · DOI · Paper page
  35. Murray-Zmijewski, 2006, p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress, Cell Death Differ, 13, 962, 10.1038/sj.cdd.4401914 · DOI · Paper page
  36. Rokaeus, 2007, PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins, Oncogene, 26, 982, 10.1038/sj.onc.1209858 · DOI
  37. Daoud, 2006, PRIMA-1 Releases the p73 bound to mutant tumor suppressor p53 in breast cancer cells, Proc Am Assoc Cancer Res, 47
  38. Rokaeus, 2010, PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73, Oncogene, 29, 6442, 10.1038/onc.2010.382 · DOI

Cited by

See all 118

Metadata

Authors
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S.
Venue
Clinical Cancer Research
Published
2011-05-01
Volume
17
Issue
9
Pages
2830-2841
ISSN
  • 1078-0432
  • 1557-3265
Cited by
118
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3168
The paper
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011). PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3168

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.